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ABSTRACT 
 Mathematical modeling and decision-making within the healthcare industry 
have given means to quantitatively evaluate the impact of decisions into diagnosis, 
screening, and treatment of diseases. In this work, we look into a specific, yet very 
important disease, the Alzheimer. In the United States, Alzheimer’s Disease (AD) is the 
6th leading cause of death. Diagnosis of AD cannot be confidently confirmed until after 
death. This has prompted the importance of early diagnosis of AD, based upon symptoms 
of cognitive decline. A symptom of early cognitive decline and indicator of AD is Mild 
Cognitive Impairment (MCI). In addition to this qualitative test, Biomarker tests have been 
proposed in the medical field including p-Tau, FDG-PET, and hippocampal. These tests 
can be administered to patients as early detectors of AD thus improving patients’ life 
quality and potentially reducing the costs of the health structure. Preliminary work has been 
conducted in the development of a Sequential Tree Based Classifier (STC), which helps 
medical providers predict if a patient will contract AD or not, by sequentially testing these 
biomarker tests. The STC model, however, has its limitations and the need for a more 
complex, robust model is needed. In fact, STC assumes a general linear model as the status 
of the patient based upon the tests results. We take a simulation perspective and try to 
define a more complex model that represents the patient evolution in time.  
Specifically, this thesis focuses on the formulation of a Markov Chain model that 
is complex and robust. This Markov Chain model emulates the evolution of MCI patients 
based upon doctor visits and the sequential administration of biomarker tests.  Data 
provided to create this Markov Chain model were collected by the Alzheimer’s Disease 
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Neuroimaging Initiative1 (ADNI) database. The data lacked detailed information of the 
sequential administration of the biomarker tests and therefore, different analytical 
approaches were tried and conducted in order to calibrate the model. The resulting Markov 
Chain model provided the capability to conduct experiments regarding different parameters 
of the Markov Chain and yielded different results of patients that contracted AD and those 
that did not, leading to important insights into effect of thresholds and sequence on patient 
prediction capability as well as health costs reduction.  
 
   
 
 
 
 
 
 
 
 
 
 
                                                 
1 The data in this thesis was provided from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
database (adni.loni.usc.edu). ADNI investigators did not contribute to any analysis or writing of this thesis. 
A list of the ADNI investigators can be found at: http://adni.loni.usc.edu/about/governance/principal-
investigators/ . 
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CHAPTER 1: INTRODUCTION  
1.1 Alzheimer’s Disease Background 
Alzheimer’s Disease (AD) is a neurodegenerative disease that impacts an individual’s 
memory, language, and reasoning.  AD, as of 2012, has affected more than 35 million 
individuals across the world and within the United States has affected over 5 million 
individuals [1].  The spread of the disease has led to prioritize research of preventing AD 
[2]. AD cannot be definitively diagnosed until after death and thus can only be likely 
diagnosed [2]. Therefore, individuals are first diagnosed with symptoms of dementia or 
most noticeably diagnosed as Mild Cognitive Impairment (MCI). Dementia and MCI are 
the first indicators of cognitive decline [2,3].  
The National Institute on Aging-Alzheimer’s Association (NIA-AA) has conducted 
and recommended research into criteria for MCI to AD conversion that incorporate the use 
of the following biomarkers: P-tau- phosphorylate tau level measured by cerebrospinal 
fluid (CSF), FDG- measured by an FDG-PET scan, and Hippo- hippocampal volume 
measured by an MRI [3, 4]. In the Journal of Alzheimer’s Disease an international panel 
of experts came together to declare that the identification and detection of AD risk factors 
are important in AD prevention [5].  Utilizing these biomarkers to accurately predict the 
conversion of MCI to AD can help with the early detection of AD. 
There have been studies using biomarkers to predict the conversion from MCI to AD 
[3]. However, these past studies have had limitations as their prediction accuracy has been 
unsuitable and the costs associated to these biomarkers as well as the time required for 
diagnosis results in a long period of time with effects on patients’ quality of life and 
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financial inefficiencies for the medical structures. One of the issues causing the 
aforementioned inefficiencies resides in the common approach to propose a single model 
for all patients. In fact, the single model assumption may result into challenges due to the 
inherent differences between patients due to, for example, physical and genetic 
characteristics.  Additionally, another limitation during these studies, is that most use 
classification techniques, and, as such, require all the test results to be known in order to 
apply any technique. In other words, these techniques are not able to embed the decision 
of which biomarker to test at which time. A classification model groups a set of interested 
subjects, such as patients into different classes based upon certain attributes [18].  
Therefore, a classification model will map an input attribute (a new individual/patient), 
into its class label (output) [6]. In these studies, the creation of a classification model 
allowed researchers to group individuals into a class of converters and non-converters with 
inaccuracies discussed in [3]. Furthermore, having all biomarkers measured at once, is 
difficult to do because at medical institutions there are constraints that include: the 
necessary resources such as personnel and tests, not enough time to conduct these tests, 
and the high associated costs administering these biomarker tests. Lastly, another limitation 
was that these biomarkers predicted conversions of MCI to AD on a numerical scale, 
meaning there is a hard cutoff for measurements to establish if a patient is in the “positive” 
or “negative” side of the biomarker measurement. This also allows classification decisions 
to be susceptible to measurement errors and unwanted bias [4]. A new model has been 
developed to combat these limitations.  
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1.2 Preliminary Work (STC) 
Si et al. in [3] proposed for the first time the Sequential Tree-Based Classifier 
(STC). The STC was designed to improve the prediction of conversion of MCI to AD and 
classify patients with their likelihood of conversions: High-Risk (HR), Low-Risk (LR), and 
inconclusive. To categorize these conversions, two biomarker cutoffs were proposed 
allowing to separate High-Risk (HR) and Low-Risk (LR) patients. In order to perform such 
prediction, the STC approach considers the biomarker values, the sequence at which the 
tests were taken, additional covariates that characterize patients such as age, sex and MCI 
outcome. Applied to each patient, the STC produces a personalized judgment of how the 
patient should be categorized by producing a personalized pair of thresholds [4]. 
Specifically, these thresholds are generated assuming that the biomarker value X is a linear 
function of the covariates and the true (unknown) class of the patient (i.e., converter/non-
converter). The model used in [3] is: 
 
𝑋𝑖 = 𝛽0,𝑖 + 𝛽𝑦,𝑖𝑌 + 𝛽𝑧,𝑖
𝑇 𝑍 + 𝜀~𝑁(0, 𝜎2)                                                                          (1)                 
                                                                                                                                   
Where 𝑋𝑖 is the type of biomarker test, 𝑍 identifies the risk factors within a sub cohort of 
patients (i.e. gender, age, etc.), 𝑌 determines the type of patient outcome, if 𝑌 = 1, the 
patient converts from MCI to AD and if 𝑌 = 0 then the patient does not. Within this 
outcome, the biomarkers cutoffs for HR and LR will further classify patients based upon 
how likely they will convert from MCI to AD. The formulation allows to compare several 
test sequences, thus determining, in turn the optimal sequence that maximizes the accuracy 
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in the classification of the patient while controlling the overall testing costs. Once the 
cutoffs are established the patients will be classified as either HR if they exceed the upper 
cutoff, LR if they are below the lower cutoff, and inconclusive if they do not fall above or 
below a certain cutoff. Biomarkers will no longer need to be tested once the patients have 
been classified as HR or LR, but if the patients are classified as inconclusive, then they 
must be tested for the next biomarker in the sequence. This sequence will continue until all 
biomarkers are tested for the inconclusive patients.  
1.3 STC Challenges 
Due to this preliminary work there exists challenges. This type of model is 
generalized and takes the assumption that there is a linear relationship between the response 
variable 𝑋𝑖 and its factors 𝑌 and 𝑍. The STC does not consider the dependency and 
interaction among the biomarker tests. This can impact the response variable, 𝑋𝑖. The 
response can result as nonlinear, inconsistent standard deviation due to different values of 
the covariates (𝑌 and 𝑍), skewed responses, and non-normally distributed errors [7]. Due 
to the current setup of the STC model, the sequence is fixed, meaning all patients must go 
through the same sequence. In the following literature reviews, the purpose for modeling 
healthcare diseases such as AD will be highlighted.  
CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction 
 The healthcare industry has vast opportunities for applying decision making models 
such as STC. The following literature review was written to determine the current 
applications for Medical Decision Making (MDM) as well as determine how a specific 
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type of modeling known as Markov Chains (MC) can be utilized in healthcare. The first 
section discusses how Operations Research methodologies can be applied to decision 
making. The second section walks through the Markov Chain modeling of HIV/AIDS 
progression. Similar to the second section, this research will use a Markov Chain to model 
the progression of AD.  
2.2 Decision Making in Healthcare 
 Healthcare costs in the United States continue to rise. In 2014, the US health cost 
exceeded $2.5 trillion [8].  It is projected that these costs will exceed other gross domestic 
price (GDP) categories [8]. Along with the issue of the rise of costs, the impact to 
individuals is just as severe as diseases continue to impact all persons of all backgrounds.  
Everyday medical decisions must be made by doctors that impact the diagnosis and 
treatment of patients.  These decisions rely on quantitative models and some applications 
from quantitative models include: breast cancer diagnosis and treatment, disease modeling, 
drug selection for HIV treatment, optimization of the timing of organ transplants, and the 
optimization of radiotherapy treatment [8]. 
 Modeling of Medical Decision Making (MDM) has become popular because past 
statistics demonstrate that medical errors due to poor decision making has attributed to a 
leading cause of death. A 1999 report stated that medical errors were responsible for 
approximately 100,000 deaths each year. From these deaths medical costs equated about 
in about $37.6 billion and of that, approximately $17 billion were because of preventable 
errors [8]. Additionally, MDM has become popular due to the increase in technology that 
allows medical doctors and personnel to collect medical information about the patient. This 
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technology gives researchers opportunities to model diseases, treatments, and 
optimizations more efficiently due to the vast amount of data available.  
 Currently healthcare policy decision makers use ad-hoc and heuristic decision-
making methodologies. These approaches currently are not capable of incorporating the 
complexity that comes along with the diagnosis, screening, and treatment of patients that 
have uncertain factors [8].  Therefore, it is important that Operations Research (OR) 
methodologies be used to combat these complex factors. OR is defined as utilizing complex 
analytical methods to make decisions. OR can be useful in healthcare and making decisions 
because complex healthcare problems can be modeled by considering the rationalization 
and the uncertain effects of making a certain decision based upon a patient’s needs [8].  
 The interest of MDM in OR is due to the need of sequential decision making under 
unpredictable factors [8].  Sequential decision making occurs because there are various 
options and decisions that doctors must make in terms of their patient’s health state [8]. 
Doctor’s decisions rely on past situations and decisions [8]. Some examples of 
unpredictability include a patient’s response to: chemotherapy, antibiotics, and access to 
limited resources such as transplant organs [8].  
 Case studies have been applied the usage of MDM. In one case study MDM 
examined the process of the screening of a mammography [8]. The decision that needed to 
be determined was when a mammogram needed to be sent for biopsy [8]. This decision 
was based upon the factors of the mammogram and the patient’s demographics [8]. In this 
case study researchers determined optimal biopsy thresholds that helped determine the 
optimal time to send the mammograms for a biopsy [8]. A second case study of MDM 
7 
 
studied the ability to develop a personalized mammography screening schedule. This 
schedule used past screening history and the patient’s personal risk characteristics [8]. This 
case study highlights the application of individualized patient care MDM can bring. The 
final case study mentioned is on making optimal decisions from resource constraints. 
Pertaining to mammograms an approach that was developed optimized thresholds over 
traditional methods and ultimately saved costs [8]. 
 Applying OR methods to MDM is still developing [8]. Major research problems 
that MDM is tackling include: personalized patient care due to prognosis and treatment, 
quantitative behavior modeling of patients, and optimizing communications between 
medical professionals and patients [8]. In this paper, the process of making decisions 
pertaining to ordering prognosis biomarker tests is studied. It is crucial to understand and 
optimize the administration of these biomarker tests because the earliest of detection of AD 
the better for effective treatment and it will reduce the costs of unnecessary tests.   
2.3 Markov Chain Modeling in Healthcare 
 In the related literature, a Markov Chain was used to forecast the progression of 
HIV/AIDS of African Americans and Caucasian Americans [9]. This type of modeling was 
used to project the number of African Americans and Caucasian Americans that are 
diagnosed with AIDS and HIV and predicts those that will be dead in the year 2030 [9]. 
Markov Chain models are used because of the ability to embed stochastic factors. 
A Markov Chain follows the characteristics of a Markov process. A Markov process is a 
stochastic process. A stochastic process occurs when a system changes unpredictably 
between different states [9]. Markov processes are frequently used to tackle healthcare 
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topics such as: genetics, determining the potency of diabetes, predicting kidney transplants, 
and analyzing disease progressions for liver cancer, breast cancer, and Alzheimer’s Disease 
[9]. These healthcare topics possess stochastic factors and are suitable to be modeled by a 
Markov Chain because of its ability to model stochastic factors.  
As an example, HIV/AIDS progression has been modeled as a discrete time Markov 
Chain with stationary transition probabilities [9]. Due to this assumption, the Markovian 
property is satisfied. The Markovian Property states that the probability of a random 
variable being in a state during a period in time only depends on the prior state before it 
and not on any other state [9]. Because of this property a Markov Chain model is useful to 
model unpredictable progression behavior even without a lot of past historical data [9]. 
Lee, Ko, Patel, Balkrishnan, and Chang et al. in [9] predicted, using the Markov Chain 
model, that Caucasian Americans currently living with HIV/AIDS is smaller than African 
Americans, but predictions show that the number of Caucasian Americans with HIV/AIDS 
will continue to increase [9].   
The methodology of formulating a Markov Chain conducted in this literature and 
explained in this section, follows the same procedure that will be explained in Chapter 3. 
The formulation of a Markov Chain needs states, transition probabilities, and the modeled 
data statistics for verification of the Markov Chain model’s results. Formulating a Markov 
Chain begins by establishing states. The states modeled in this literature follow the state 
notation: S = 𝑆1, 𝑆2, … , 𝑆𝑛. 𝑆1 = the rate of vulnerable people (V), 𝑆2 = the rate of people 
diagnosed with HIV (H), 𝑆3 = the rate of people diagnosed with AIDS (A), 𝑆4 = the rate of 
deaths from HIV/AIDS (D). States 𝑆1, 𝑆2, and 𝑆3 are modeled as transient states and 𝑆4 is 
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modeled as an absorbing state [9]. Transient states are states that the patient can transition 
into and out of and an absorbing state is when the patient will never transition out of that 
state. The following figure represents the transitions among the different states.  
 
 
 
 
 
The next step in modeling a Markov Chain would be to use the provided data for 
the model formulation. In this literature study, four years of data (2006-2009) from the 
Centers of Disease Control and Prevention (CDC) and the Prevention HIV/AIDS 
Surveillance Report from 2009 were used. This data provided the rates of African 
Americans and Caucasian Americas for each state. These rates then were calculated to their 
respective transition probabilities. These transition probabilities are represented in Figure 
1 with the notation of 𝑝𝑖𝑗, where i represents the prior state and j represents the next state. 
Two different transition matrices were constructed, 𝑇𝐵 = African Americans and 𝑇𝑊= 
Caucasian Americans.  
The last step in modeling a Markov Chain would be to verify this model with the 
actual statistics of those affected with HIV/AIDS [9]. This verification allows the model to 
Figure 1: Transition Diagram for HIV/AIDS 
(Source [9]) 
 
Figure 2: African American Transition 
Matrix (Source [9]) 
Figure 3: Caucasian American Transition 
Matrix (Source [9]) 
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be assessed on its accuracy in predicting and forecasting. This literature provided an 
overview of the needed elements in developing a Markov Chain model and informed the 
methodology process used in this thesis. 
CHAPTER 3: METHODOLOGY 
3.1 Method Overview 
Due to the research goal of creating a Markov Chain model, the following work 
was outlined. The highlighted sections represent the focus of research conducted. 
Preliminary Work 
(STC)
Markov Chain 
Model 
Formulation
Simulate MC Model 
Validate
 
Figure 4: Method Overview 
The basis of this research is the formulation of a Markov Chain model that models 
the evolution of MCI patients based upon doctor visits. This is done to create the 
benchmark needed to understand the impact of the sequential order of the administration 
of the biomarker tests decided by doctors. As mentioned in section 1.2 the STC model has 
its limitations of not being able to effectively model the dependency between the tests and 
the uncertainty characterizing the process if not through additive gaussian noise. The 
remaining part of this chapter will discuss the initial data used to create the Markov Chain 
model and will discuss the steps of formulating the Markov Chain model. Techniques and 
results will additionally be explained. Chapter 4 will discuss the simulation of the Markov 
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Chain model and the results of different experiments conducted. In conclusion, Chapter 5 
will recap the purpose and objective of this research as well as its numerical results.  
3.2 Data Description 
The data used to create the Markov Chain model was obtained from the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu) on July 
31st, 2013 [3]. The ADNI originated in 2003 as a public-private partnership, spearheaded 
from Michael W. Weiner, the Principal Investigator. The principal goal of ADNI has 
composed of testing whether serial magnetic resonance imaging (MRI), positron emission 
tomography (PET), other biological markers, and clinical and neuropsychological 
assessment can be accumulated to measure the progression of MCI and early AD. To obtain 
more information visit www.adni-info.org.  
This Markov Chain model was created from a total of 144 patient’s records. These 
144 records reflected patients at the MCI stage and observed the patient’s progression for 
two years of either contracting AD or not contracting AD. If a patient contracted AD, the 
value assigned to that specific patient and record was recorded as 1 and 0 otherwise. From 
these 144 records, 72 patients contracted AD and the other 72 patients did not convert to 
AD. All 144 records included the biomarker test ranges of p-Tau, FDG-PET, and Hippo. 
An example of the framework of this ADNI data is represented below. 
 Patient 
Number 
Conversion- 
 2 years 
p-Tau FDG-PET Hippo 
1 1 - - - 
2 0 - - - 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
Table 1: ADNI Data Framework 
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3.3 Markov Chain Formulation 
3.3.1 Assumptions 
Due to the multiple factors of modeling the evolution of a patient’s visits to the 
doctor, assumptions were made to create the Markov Chain model. The first assumption 
was that all patients belonged to same type of population and therefore all were considered 
homogeneous. The second assumption was that the doctors administered a specific 
biomarker test randomly. For example, if a patient was not given any tests yet, the patient 
had a 1 3⁄  chance of being administered the p-Tau test. Then if the patient still was not 
diagnosed of either contracting AD or not, another biomarker test would be randomly 
administered, and the remaining tests would be the FDG-PET and the Hippo test. If the 
next biomarker test administered was the FDG-PET test, the probability of that test being 
chosen would be 1 2⁄ . Then the remaining probability of being administered the Hippo test 
would be 1.  
3.3.2 States 
States within a Markov Chain are dependent on the decision maker. The states of 
the system will be represented as an overall vector of 𝑋 composed of vectors: 𝑋𝑇 and 𝑋𝐻 
based upon the 𝑡𝑡ℎ doctor visit. The two vectors will represent the biomarker tests (𝑋𝑇)  
and the patient’s health state (𝑋𝐻). The biomarker tests will consist of three tests: {p-Tau 
test, FDG-PET test, and a hippocampal (Hippo) test}. If a test in 𝑋𝑇 was performed then it 
would take a value of 1, otherwise 0. The patient’s health state after being administered a 
biomarker test will result in: contraction of AD, no contraction of AD, or inconclusive. The 
patient health states in 𝑋𝐻 will take a value of the associated states in abbreviation form of: 
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no detection of AD = NAD, detection of AD = AD, and Inconclusive = I. Both vectors will 
be represented as an overall vector: 𝑋 = [𝑋𝐻, 𝑋𝑇]. The vectors are represented below.  
Patient Health State Vector: 
𝑋𝐻𝜖ℝ
3 =[no AD = NAD, AD = AD, Inconclusive = I]                
 
Biomarker Test Vector: 
𝑋𝑇𝜖ℝ
3 = [p-Tau, FDG-PET, Hippo] 
𝑋𝑇 = {
1,  𝑖𝑓 𝑐𝑜𝑟𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑖𝑛𝑔 𝑡𝑒𝑠𝑡 𝑡𝑎𝑘𝑒𝑛
0,  𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
 
 
 
Overall Vector 
𝑋 = [𝑋𝐻, 𝑋𝑇]                                                                                                                     (2) 
 
 
Thus, the overall vector of both the biomarker test and the patient’s health state will be 
mathematically represented as:  
 
𝑃(𝑋𝑡+1 = 𝑗 |𝑋𝑡 = 𝑖) =  𝑝𝑖𝑗                                                                                                                 (3)      
𝑡 = 1,2, … is the index of the visit.  
 
Where 𝑖, 𝑗 represents states at time 𝑡 and 𝑝𝑖𝑗 represents the probability of the states after a 
transition from one state to another. For example, state, [1, 0, 1, AD] means that the p-Tau 
and the Hippo test were administered and the MCI patient contracted AD. By using a 
Markov Chain model, the future state of the patient can be predicted based upon the current 
state of the patient. This Markov Chain is based off the Stationary Assumption, where the 
transition states are independent of the doctor visit, 𝑡 [10]. 
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3.3.3 Transition Matrix and Diagram 
Based upon the formulated states a transition matrix could be created. A total of 22 
states existed. Each possible transition from each state was traced and formulated a 22 by 
22 matrix. Within these transition states exists absorbing states. Absorbing states are states 
when the patient can longer progress further in being administered biomarker tests. This 
means that the patient has converted from MCI to AD or the patient has not converted to 
AD and is recognized as the state, NAD. Patients recognized as AD or NAD no longer are 
administered biomarker tests and are no longer studied further in the Markov Chain. The 
transient states, those that are not absorbing states are patients that are recognized as being 
in an Inconclusive (I) state. These patients fall within an Inconclusive diagnosis once 
administered a biomarker test or more than one biomarker test. The Markov Chain is 
completed when all three tests are administered. There is a total of 36 states that have 
transition probabilities. Each transition probability must be multiplied by the assumption 
that the doctor randomly administers a biomarker test. The following matrix shows the 
highlighted 36 states. These 36 states represent transition probabilities, “p”, and the 
probabilities of randomly administering a biomarker test being multiplied.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Transition Matrix of Markov Chain Model 
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The calculation of these transition probabilities will be discussed further in 3.4.1.d 
as well as the results. In addition, to formulating a transition matrix, a transition diagram 
also can be created to visually see the possible paths that a patient will undergo as the 
patient visits their doctor and is given a biomarker test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The golden highlighted states in Figure 6 represent the transient states as these 
states are Inconclusive patients (I). The absorbing states are pictured as the states with 
recurring arrows and the red highlighted states are the conclusive states of the Markov 
Chain model. The conclusive states are all the possible three states: AD, NAD, I, once all 
tests have been administered. 
[0, 0, 0, I]
[1,0,0,AD] [1,0,0,NAD] [1,0,0,I] [0,0,1,AD] [0,0,1,NAD] [0,0,1,I][0,1,0,NAD] [0,1,0,I][0,1,0,AD]
[1,1,0,AD] [1,1,0,NAD] [1,1,0,I]
[0,1,1,AD] [0,1,1,NAD] [0,1,1,I]
[1,0,1,AD] [1,0,1,NAD] [1,0,1,I]
[1,1,1,AD] [1,1,1,NAD] [1,1,1,I]
Figure 6: Transition Diagram of Markov Chain Model 
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3.4 Estimation of Markov Chain Components 
3.4.1 Estimation Techniques Introduction 
Different approaches were applied in the attempt to calculate the transition 
probabilities. The first necessary step was to normalize the data. This allowed the 
calculation of probabilities to be easier. The first attempt to calculate the transition 
probabilities was to use the method of input modeling, however this had its limitations 
and will be discussed further in section 3.4.1.c. The next plausible and selected method 
was to solve the transition probabilities by utilizing Empirical Cumulative Distribution 
Functions.  
3.4.1.a Data Normalization 
The calculation of these transition probabilities is important to understand the 
impact of the sequential sequence of biomarker test administration. Prior to calculating 
these probabilities with the original data explained in section 3.3, the data must be 
normalized. This is because the ranges of these biomarker tests must be taken into 
consideration as the p-Tau, FDG-PET, and Hippo tests all have different test values and 
ranges. The p-Tau test’s values range from a minimum of 14 to a maximum of 171, the 
FDG-PET test’s values range from a minimum of 0.88 to a maximum of 1.60, and the 
Hippo test’s values range from a minimum of 1941 to a maximum of 4807. These test 
values must be normalized to adhere to different ranges. This normalization of the data is 
important for determining the joint density functions due to the combination of 
administered tests. The statistical software R was used to normalize this data from 0 to 1. 
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3.4.1.b Bayes’ Formulation 
The Markov Chain transition probabilities will be estimated using Bayesian 
methods. These Bayesian methods will help correspond the data with the current Markov 
Chain model. Bayes’ theorem is made up from a posterior probability and a prior 
probability [17]. Bayes’ theorem interchanges conditioning and updates based upon new 
information. One example from an absorption state such as [1, 1, 0, AD] states that the 
patient was administered the p-Tau and FDG-PET test and resulted in converting from MCI 
to AD. This specific state, [1, 1, 0, AD] is represented in the following Bayes’ formulation:  
 
𝑃(𝐴𝐷 |𝑝𝑡𝑎𝑢, 𝐹𝐷𝐺𝑝𝑒𝑡) =  
𝑃(𝑝𝑡𝑎𝑢,𝐹𝐷𝐺𝑝𝑒𝑡 | 𝐴𝐷)∗𝑃(𝐴𝐷)
𝑃(𝑝𝑡𝑎𝑢,𝐹𝐷𝐺𝑝𝑒𝑡)
                                                                 (4) 
 
 
𝑃(𝐴𝐷 |𝑝𝑡𝑎𝑢, 𝐹𝐷𝐺𝑝𝑒𝑡) represents the posterior probability, where this is what 
occurs after both tests have been administered. 𝑃(𝑝𝑡𝑎𝑢, 𝐹𝐷𝐺𝑝𝑒𝑡 | 𝐴𝐷) represents the 
likelihood that given that the patient converted to contracting Alzheimer’s Disease from 
being in an Inconclusive state, it calculates what the chance of that occurring due to being 
administered the p-Tau test and the FDG-PET test. The prior probability, 𝑃(𝐴𝐷) is what 
occurs before tests have been administered. The evidence of this formula is 
𝑃(𝑝𝑡𝑎𝑢, 𝐹𝐷𝐺𝑝𝑒𝑡) because it is known that these tests were administered. 
3.4.1.c Input Modeling 
Input models identify probability distributions from collected data. These 
probability distributions are determined from histograms. Histograms for continuous data 
such as the data in this research, correspond to the probability density function (PDF) of a 
theoretical distribution [11]. A line is drawn in the center of the bars of the histograms for 
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each interval based upon its frequency [11]. From these PDFs the calculation of 
probabilities could be calculated by using the parameters of these distributions, which 
includes the mean and standard deviation [11]. Software such as JMP allows users to input 
interested data into the software and a PDF and its parameters are provided. In this research, 
JMP was initially used to determine the PDFs of marginal densities and the PDFs of all 
tests individually. The following tables are examples of PDFs for the absorption state, [1, 
1, 0, AD]. 
Marginal Density of FDG-PET: 𝒇𝑭𝑫𝑮𝑷𝑬𝑻| 𝑨𝑫 
Type of 
Distribution PDF Graph Parameters 
 
 
 
 
Normal 
 
 
 
 
 
 
 
Mean = 
0.460 
Standard 
Deviation 
= 0.189 
Table 2: Marginal Density of FDG-PET|AD 
Marginal Density of p-Tau: 𝒇𝒑𝒕𝒂𝒖| 𝑨𝑫 
Type of 
Distribution PDF Graph Parameters 
 
 
 
 
Exponential 
 
 
 
 
 
 
 
Standard 
Deviation 
= 0.305 
Table 3: Marginal Density of p-Tau|AD 
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Density of FDG-PET: 𝒇𝑭𝑫𝑮𝑷𝑬𝑻 
Type of 
Distribution PDF Graph Parameters 
 
 
 
 
Normal 
 
 
 
 
 
 
 
Mean = 
0.427 
Standard 
Deviation 
= 0.178 
Table 4: Density of FDG-PET 
Density of p-Tau: 𝒇𝒑−𝑻𝒂𝒖 
Type of 
Distribution PDF Graph Parameters 
 
 
 
 
Exponential 
 
 
 
 
  
 
Standard 
Deviation 
= 0.224 
Table 5: Density of p-Tau 
Unfortunately, this method could not be conducted further because joint variables 
cannot be analyzed using JMP. The posterior probability illustrated in equation 4, 
𝑃(𝐴𝐷 |𝑝𝑡𝑎𝑢, 𝐹𝐷𝐺𝑝𝑒𝑡) could not be analyzed, nor provided a PDF and its parameters.                                                             
3.4.1.d Conditional Probabilities 
In this research, it is important to understand the relationship between two and three 
random variables. These random variables represent the values of the biomarker tests. Due 
to the lack of an input modeling software that can provide the joint PDF of two and more 
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continuous random variables, the conditional probability will be utilized. The formation of 
a conditional probability will aid in determining the joint probability, 𝑓𝑋,𝑌(𝑥, 𝑦): 
 
𝑓𝑋|𝑌(𝑥) =  
𝑓𝑋,𝑌(𝑥,𝑦)
𝑓𝑌(𝑦)
                                                                                                                      (5) 
 
For example, equation 5 states the interest of determining the probability of X given 
Y is the joint probability of X and Y over the marginalized probability of Y.  In this 
research, equation 5 is used to help calculate the probability of an example of transitioning 
from state [1, 0, 0, I] to [1, 1, 0, AD]. These two states mean that a patient is transitioning 
from a state of Inconclusive once given the p-Tau test, to a state of converting to AD after 
being given the FDG-PET test next.  
3.4.1.e Empirical Cumulative Distribution Function (ECDF) 
Before illustrating an example of a calculation of transition probabilities the 
thresholds of the three tests must be established as these thresholds determined when a 
patient would convert to AD, NAD, or I. Thresholds are established because probabilities 
are calculated by counting the number of patients below, above, or in between the 
thresholds. These counts illustrate the approach of utilizing Empirical Cumulative 
Distribution Functions (ECDF). ECDFs resample from the data collected and are used 
when there are no suitable theoretical distributions [11]. Since there are no viable 
theoretical distributions from input modeling due to joint variables, ECDFs illustrate the 
best option in calculating the transition probabilities.  
The thresholds established for each biomarker were calculated by using the 
normalized test value data. The thresholds included upper bounds and lower bounds. These 
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bounds were calculated by determining the 25% quantile and 75% quantile of all test values 
for each test. The quantiles’ values were calculated using R software. The p-Tau’s upper 
bound is 0.2951 and the lower bound is 0.1183. If a data record represented a p-Tau test 
value of 0.2951 or above, then that patient converts to AD and if a p-Tau test value that is 
equal or less than 0.1183 does not convert to AD and is assigned as a state of NAD. A p-
Tau test value that falls between the lower bound and upper bound values results in an 
Inconclusive (I) state. The FDG-PET’s upper bound is 0.5266 and FDG-PET test values 
that are equal to or greater do not have AD and are assigned as a state of NAD. The lower 
bound of the FDG-PET is 0.3237 and test values that are equal to or less are assigned a 
state of AD. Test values between the upper bound and lower bound values are assigned a 
state of Inconclusive (I). The Hippo’s upper bound is 0.5456 and test values that are equal 
and greater than are assigned a state of NAD and do not convert to AD. The lower bound 
of the Hippo test is 0.3235 and test values that are equal and less than are assigned a state 
of AD and converts AD. Test values that are between the upper bound and lower bound 
values are assigned a state of Inconclusive (I). Tables 6, 7, and 8 represent the summaries  
of the thresholds and patient state outcomes.  
Table 6: p-Tau Thresholds and Outcomes 
Test Normalized Data 
 
FDG-PET 
Thresholds Outcome 
≥ 0.5266Upper Bound NAD 
≤ 0.3237Lower Bound AD 
(0.3237, 0.5266) I 
Table 7: FDG-PET Thresholds and Outcomes 
Test Normalized Data 
 
p-Tau 
Thresholds Outcome 
≥ 0.2951Upper Bound AD 
≤ 0.1183Lower Bound NAD 
(0.1183, 0.2951) I 
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Test Normalized Data 
 
Hippo 
Thresholds Outcome 
≥ 0.5456Upper Bound NAD 
≤ 0.3235Lower Bound AD 
(0.3235, 0.5456) I 
Table 8: Hippo Thresholds and Outcomes 
After calculating these thresholds and determining the corresponding outcomes the 
collected data for each test was organized in a total of 13 intervals and each interval’s width 
was 1 12⁄ . These number of intervals and interval widths were decided upon the basis of 
constructing a histogram. Justification for following the basis of the construction of a 
histogram is because histograms are known as a frequency distribution charts and since 
ECDFs were the best option in determining transition probabilities, this organization of 
data would allow the feasibility of counts. The number of intervals, 13, for each test was 
determined by using the rule of thumb in constructing histograms, where the number of 
intervals is the square root of the total number of data records [12].  Since there is a total 
of 144 data records the square root of 144 is 12, however the interval width is the best when 
it is equal as possible and the interval width was calculated by inverting 12 to equal 1 12⁄ =
 0.0833 and by adding each interval width it equated to a total 13 equal width intervals 
[12]. Table 9 serves as an example of the intervals for each test. 
 
 
 
 
 
 
Table 9: Intervals for Each Test 
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Figure 7: ECDF Graph of p-Tau and FDG-PET tests 
F
D
G
-P
E
T
 
 L
o
w
er 
B
o
u
n
d
 
 =
 In
terv
a
l 4
 
F
D
G
-P
E
T
 
U
p
p
er 
B
o
u
n
d
 
 =
 In
terv
a
l 7
 
An example of utilizing the ECDF approach, is as follows, where the interest is 
calculating the probability of transitioning to state [1, 1, 0, AD]. This state means that both 
the p-Tau and the FDG-PET test were administered to this patient and this patient 
converted to obtaining AD. This interested resultant state has two possible past states: [0, 
1, 0, I] and [1, 0, 0, I], where the patient could have first been given the FDG-PET test and 
resulted in an Inconclusive test status or the patient could have been first given the p-Tau 
test and resulted in an Inconclusive test status. The ECDF of a p-Tau test and FDG-PET 
test is shown in Figure 7. 
 
 
 
 
 
 
 
 
 The X-axis represents the intervals associated to the corresponding test values. The 
p-Tau lower bound corresponds to interval 2 and the upper bound interval of p-Tau is 4. 
The FDG-PET lower bound corresponds to interval 4 and the upper bound interval of FDG-
PET is 7. The corresponding intervals contains the 25% and 75% quantile values. These 
intervals are determined by referencing Table 9.  
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From these corresponding intervals the probabilities were calculated by the 
following equations that utilize the conditional probabilities of the previous states.  
 
𝑃𝑝𝑇𝑎𝑢(𝑝𝑇𝑎𝑢 ≥  𝑝𝑇𝑎𝑢
𝑈𝐵 | 𝐹𝐷𝐺𝑝𝑒𝑡 ∈  [ 𝐹𝐷𝐺𝑝𝑒𝑡𝑈𝐵, 𝐹𝐷𝐺𝑝𝑒𝑡𝐿𝐵]) ∗ 𝑃(𝑐ℎ𝑜𝑜𝑠𝑒 𝑝𝑇𝑎𝑢 𝑡𝑒𝑠𝑡 𝑟𝑎𝑛𝑑𝑜𝑚𝑙𝑦 =  1 2⁄ )       (6) 
 
𝑃𝐹𝐷𝐺𝑝𝑒𝑡(𝐹𝐷𝐺𝑝𝑒𝑡 ≤  𝐹𝐷𝐺𝑝𝑒𝑡
𝐿𝐵 | 𝑝𝑇𝑎𝑢 ∈  [ 𝑝𝑇𝑎𝑢𝑈𝐵, 𝑝𝑇𝑎𝑢𝐿𝐵]) ∗ 𝑃(𝑐ℎ𝑜𝑜𝑠𝑒 𝐹𝐷𝐺𝑝𝑒𝑡 𝑡𝑒𝑠𝑡 𝑟𝑎𝑛𝑑𝑜𝑚𝑙𝑦 =  1 2⁄ )    (7) 
 
 
Equation 6 references the probability of being administered the FDG-PET next after 
initially being administered the p-Tau test. Equation 7 references the probability of being 
administered the p-Tau test next after initially being administered the FDG-PET test. The 
notation UB and LB are abbreviated respectively for upper bound and lower bound. 
Equation 6 states that the probability that the test, p-Tau is administered after FDG-
PET is when the test value is equal to or greater than the upper bound of p-Tau and that is 
when the test value is equal to or greater than 0.2951 and this is when the corresponding 
interval is 2. Therefore, the probability of this transition is calculated by counting all the 
test value instances of p-Tau that are greater than interval 2 when the FDG-PET is in the 
state of Inconclusive and that occurs when the test value is between the lower bound and 
upper bound of FDG-PET, (0.3237, 0.5266) which equates to the intervals 5 and 6 which 
are between the lower bound interval 4 and upper bound interval 7. Then that count is 
divided by the sum of all p-Tau test values within that Inconclusive state interval of FDG-
PET and that equals the transition probability. That transition probability is then multiplied 
by the random assumption probability that the biomarker tests are randomly chosen. 
Equation 7 follows the same suit, however with the switched condition variable of p-Tau. 
The following table shows the respective transition probabilities for equations 6 and 7. 
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Equation Past State Current State Transition 
Probability 
6 [0, 1, 0, I] [1, 1, 0, AD] 14% 
7 [1, 0, 0, I] [1, 1, 0, AD] 19% 
Table 10: Two Different Transition Probabilities for p-Tau and FDG-PET Tests 
3.4.2 Results Introduction 
From utilizing the ECDF approach, the following sections demonstrate the results 
of the calculations of all the possible transition probabilities for each feasible transition. 
The absorption probabilities of the absorbing states of the Markov Chain are further 
calculated and shown by the utilization of reordering the transition matrix of the position 
of transient probabilities and the position of the probabilities from transient to absorbing 
states, adding a submatrix of zero entries, and adding the submatrix of an identity matrix 
[13].   
3.4.2.a Transition Probabilities 
The following figure represents the calculations of all the transition probabilities of 
transient and absorption states. All calculations were conducted using Excel, specifically 
Pivot Tables, and nested functions.  
 
 
Figure 8: Transition Matrix Results 
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These transition probabilities of this Markov Chain are verified and confirmed as each row 
sums up to 1. As shown in Figure 5, the transition matrix framework, the same 36 
probabilities are calculated and are highlighted.  
3.4.2.b Markov Chain Calculations 
 
The Markov Chain being modeled is classified as an absorbing Markov Chain because 
it contains both transient and absorbing states [13]. There is interest in the absorbing chain 
because there are inquires of: 
1) What is the probability that a patient will end up in an absorbing state given that 
the patient started in a specific transient state? [15]. 
2)  How many expected time periods does a patient spend in a transient state before 
the patient reaches an absorption state? [15]. 
The created transition matrix shown in Figure 8, is reorganized by classes of states by 
the following organization and notation:  
P = s – m columns 
(Transient States) 
m columns 
(Absorbing States) 
s – m rows 
(Transient States) 
 
Q 
 
R 
m rows 
(Absorbing States) 
 
0 
 
I 
Table 11: Reorganization of Transition Matrix Framework 
The notations are as follows, P corresponds to the transition matrix in Figure 8, s = 
number of states = 22, and m = number of absorbing states = 15, Q = Transient State 
Probabilities, R = Absorbing State Probabilities, 0 = Submatrix of zero elements, I = 
Identity Matrix [14, 15]. The reorganized matrix represented in Figure 9, helps answer the 
first and second inquiry mentioned previously. The reorganized matrix and the following 
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equations were calculated using MATLAB. The first inquiry is calculated with equation 8 
and the second inquiry is calculated with equation 9. 
(𝐼 − 𝑄)−1 ∗ 𝑅                                                                                                                                            (8)     
(𝐼 − 𝑄)−1                                                                                                                          (9) 
 
 
Additionally, the transient states and absorption states are outlined in Table 12. 
Transient States Absorbent States 
[0, 0, 0, I] [1, 0, 0, I] [1, 0, 0, AD] [0, 1, 0, AD] 
[0, 1, 0, I] [0, 0, 0, I] [0, 0, 1, AD] [1, 0, 0, NAD] 
[1, 1, 0, I] [1, 0, 1, I] [0, 0, 1, NAD] [0, 1, 0, NAD] 
[0, 1, 1, I]  [1, 1, 0, AD] [1, 0, 1, AD] 
  [1, 1, 0, NAD] [1, 0, 1, NAD] 
  [0, 1, 1, AD] [0, 1, 1, NAD] 
  [1, 1, 1, AD] [1, 1, 1, NAD] 
  [1, 1, 1, I]  
Table 12: Transient and Absorbent States of Markov Chain 
Figure 9: Reorganized Transition Matrix 
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The probabilities for the first inquiry are represented in Figure 10 and the expected number 
of time periods for the second inquiry are represented in Figure 11.  
Figure 10: Markov Chain Model Absorption Probabilities 
 
Figure 11: Expected # of Time Periods in Transient State Prior to Absorption 
The absorption probabilities in Figure 10 follow a trend that as more tests are 
administered there is a higher likelihood of a patient not contracting AD. An example 
interpretation of Figure 11, states that starting at state [0, 0, 0, I] will result in the expected 
number of time periods that a patient stays in state [0, 0, 0, I] is 1, the expected number of 
time periods a patient stays in state [1, 0, 0, I] is 0.081, and so forth.   
CHAPTER 4: NUMERICAL RESULTS 
 
4.1 Introduction 
As with any type of model formulation, it is best practice to validate and verify the 
model. Model validation encompasses the interaction between the real system, which is the 
research problem of optimizing the biomarker test administration policy decisions that 
improve the accuracy in detecting patients that will contract Alzheimer’s Disease and those 
who do not, to the Markov Chain model of that system [11]. This interaction can be 
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validated with the verification of the Markov Chain model to a simulation of the model. 
The Markov Chain model can be verified by producing simulations of all possible 
transitions from transient states to absorbent states. Simulations of the Markov Chain 
model will show the impact of the lower bound and upper bound thresholds. As stated 
previously in this paper, the thresholds determine the likelihood of a patient contracting 
AD or not. The simulations of the Markov Chain model are conducted by a coded 
simulation. The simulation code is explained in the following section. 
4.1.1 Simulation Background  
Simulation code was created using MATLAB. This simulation code runs 1,000 
replications of modeling sample paths from transient states to the absorbent states. The 
input of the transition matrix shown in Figure 9 and the initial transient state must be 
manually executed in the MATLAB code. The sample paths from these replications are 
then used to calculate the absorbing probabilities. 
4.1.2 Markov Chain Model Verification 
The initial absorption probabilities from the Markov Chain model shown in Figure 
10 must be compared to the calculated absorption probabilities from the simulation model. 
The Markov Chain model can only be verified if there is no difference between the Markov 
Chain absorption probabilities and simulation model absorption probabilities.  This 
verification step involves a similar procedure conducted in section 3.4.1.e, when transition 
probabilities were empirically calculated. The simulation code produced all the possible 
states that could be reached from a starting state of a transient state. Table 13 is an example 
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of the possible transition paths for the initial state, [0, 0, 0, I]. Table 14 serves as a reference 
to associate each numerical state from the simulation to the corresponding vector state. 
# of Reps Initial State State 1 State 2 State 3 
1 1 13 0 0 
2 1 4 19 0 
3 1 13 0 0 
4 1 12 0 0 
5 1 10 0 0 
… … … … … 
996 1 10 0 0 
997 1 12 0 0 
998 1 9 0 0 
999 1 3 5 20 
1000 1 11 0 0 
Table 13: Sample Transition Path from Simulation Code 
Transient States Absorbent States Absorbent States 
Simulation 
State Vector State 
Simulation 
State 
Vector 
State 
Simulation 
State Vector State 
1 [0,0,0, I] 8 [1,0,0, AD] 15 [1,0,1, AD] 
2 [1,0,0, I] 9 [0,1,0, AD] 16 [1,1,0, NAD] 
3 [0,1,0, I] 10 [0,0,1, AD] 17 [1,0,1, NAD] 
4 
[0,0,1, I] 
11 
[1,0,0, 
NAD] 18 
[0,1,1, AD] 
5 
[1,1,0, I] 
12 
[0,0,1, 
NAD] 19 
[0,1,1, NAD] 
6 
[1,0,1, I] 
13 
[0,1,0, 
NAD] 20 
[1,1,1, AD] 
7 [0,1,1, I] 14 [1,1,0, AD] 21 [1,1,1, NAD] 
    22 [1,1,1,I] 
Table 14: State Reference 
From Table 13, each time an absorbent state, identified as 8-22 was listed, the count 
was summed for each absorbent state and divided by the total number of repetitions 
conducted from the simulation which was 1,000. The following equation is the equation 
used to calculate each probability in Figure 12. 
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𝑡𝑜𝑡𝑎𝑙 𝑐𝑜𝑢𝑛𝑡 𝑜𝑓 𝑎𝑏𝑠𝑜𝑟𝑏𝑡𝑖𝑜𝑛 𝑠𝑡𝑎𝑡𝑒 𝑣𝑖𝑠𝑡𝑒𝑑
1,000
                                                                         (10) 
Figure 10, the Markov Chain model absorption probabilities and Figure 12, the 
simulation model’s absorption probabilities are then statistically compared by conducting 
a F-test. A F-test tests the hypothesis on the equality of the variances of two different data 
sets [16]. Equation 11 illustrates the null (𝐻0) and alternate (𝐻𝑎) hypothesis being tested.  
𝐻0: 𝜎1
2 =  𝜎2
2 
𝐻𝑎: 𝜎1
2 ≠  𝜎2
2                                                                                                                                            (11) 
 
This states that if the variance within the Markov Chain model absorption 
probabilities and the variance within the simulation model absorption probabilities are not 
statistically significant the two sets of absorption probabilities are essentially the same. 
Table 15 contains the F-test results: 
  Markov Chain Model  Simulation Model 
Mean 0.066711929 0.066666667 
Variance 0.011544883 0.011299186 
Observations 105 105 
df 104 104 
F 1.021744659  
P(F<=f) one-tail 0.456433199  
F Critical one-tail 1.382732799   
Table 15: F-test Results 
Figure 12: Calculated Simulation Absorption Probabilities 
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Since the F statistic, 1.02 is smaller than the F critical value, 1.38, the null 
hypothesis, 𝐻0 is not rejected. This means that the two data sets’ variances are equal. This 
verifies that the simulation model and the Markov Chain model do no differ. This proves 
that the Markov Chain can effectively model different types of parameter changes that are 
conducted in the following section.  
4.2 Experiments 
The parameter changes for this Markov Chain model are conducted by simulating 
different experiments. Two types of experiments are demonstrated. The first experiment is 
the tightening of the AD classification thresholds. The thresholds mentioned in tables 6, 7, 
and 8 are the values that determine the patients’ classification of contracting AD or not. 
The second experiment involves testing all possible biomarker test sequences. Both 
experiments were decided upon because both are two main parameter inputs in simulating 
the Markov Chain.  
These experiments were conducted to demonstrate the impact the thresholds and 
specified test sequences can have on the probability of patients contracting AD and the 
expected time spent in transient states before absorption. Simulations of these experiments 
of the Markov Chain model provide evidence that the Markov Chain can efficiently model 
different parameters of the evolution of MCI patients.  The Markov Chain is a more 
complex model than the STC model and these simulations demonstrate that the Markov 
Chain model can replace the STC model due to its capability of simulating complex 
parameters. 
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4.2.1 Tightening AD Threshold  
The F-test results verified the ability of the Markov Chain to model different 
parameters of the thresholds. The thresholds that classify patients as converting to AD was 
tightened. The threshold for the p-Tau test was changed from representing the 75% quantile 
to tightening it to the 65% quantile. The AD conversion threshold for the FDG-PET test 
changed from the 25% quantile to the 35% quantile. The Hippo test’s threshold for AD 
conversion changed from the 25% quantile to the 35% quantile. The highlighted data 
values changed accordingly:  
Table 16: p-Tau Thresholds and Outcomes 
Test Normalized Data 
 
FDG-PET 
Thresholds Outcome 
≥ 0.5266Upper Bound NAD 
≤ 0.3466Lower Bound AD 
(0.3237, 0.5266) I 
Table 17: FDG-PET Thresholds and Outcomes 
Test Normalized Data 
 
Hippo 
Thresholds Outcome 
≥ 0.5456Upper Bound NAD 
≤ 0.3627Lower Bound AD 
(0.3235, 0.5456) I 
Table 18: Hippo Thresholds and Outcomes 
As demonstrated in Chapter 3, these threshold values correspond respectively to 
established numeric interval values in Table 9. These intervals aid in calculating the 
transition probabilities for the newly established AD thresholds. As demonstrated in the 
example in section 3.4.1.e, the transition probabilities are calculated in the same manner 
and are represented in the following transition matrix: 
Test Normalized Data 
 
p-Tau 
Thresholds Outcome 
≥ 0.23971Upper Bound AD 
≤ 0.1183Lower Bound NAD 
(0.1183, 0.2951) I 
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The Markov Chain model absorption probabilities seen in Figure 14, were also calculated 
in the same manner using MATLAB as explained in section, 3.4.2.b. 
 
 
 
The expected number of time periods spent in a transient state prior to entering an absorbent 
state is represented by Figure 15. These time periods were calculated by equation 9.  
 
 
 
 
 
 
4.2.1.a Experiment 1 Data Comparison 
A comparison between the absorption probabilities of tightened AD thresholds and 
the original thresholds was conducted. A F-test resulted in a F statistic of 1.55 and F critical 
Figure 14: Absorption Probabilities for Adjusted AD Threshold 
Figure 15: Expected # of Time Periods in Transient State Before Absorption State from New 
AD Thresholds 
Figure 13: Transition Matrix for Adjusted AD Thresholds 
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value of 1.40. Since the F statistic is greater than the F critical value, this stated that there 
was statistically enough evidence to reject the null hypothesis that the variances between 
the two sets are the same. Comparing Figure 10 and Figure 14 side-by-side shows that 
Figure 14 has one less transient state than Figure 10. This is because due to a tighter AD 
threshold, the Inconclusive interval for p-Tau was non-existent and this resulted in zero 
visits to state, [1, 0, 0, I]. Therefore, because of the exclusion of this state, there is a 
significance difference among the original thresholds and new thresholds. Since, there were 
no possible visits to an Inconclusive state, it can be inferred that the new tighter AD 
thresholds will perform better in confidently classifying patient’s conversions to attaining 
AD or not attaining AD.  Additionally, there will be a subgroup of patients that will not 
need to be administered more biomarker tests and this would lead to a decrease of the cost 
of tests and time of diagnosis.  
Another set of comparisons was conducted. The initial data from ADNI mentioned 
in section, 3.2, were compared against the absorption probabilities from Figure 14 and 
compared against the absorption probabilities provided in Figure 10. The total probability 
of patients that contracted AD and the total probability of patients that did not contract AD, 
denoted as NAD, were analyzed among these three data sets. The Inconclusive state, I, was 
not compared between all these 3 different data sets because the patient data set did not 
have information about patients that were classified as Inconclusive. 
The patient data set classified that 50% patients contracted AD and the other 50% 
did not contract AD. Table 19 demonstrates the total probabilities of patients contracting 
AD and not contracting AD (NAD) from Figure 14 which represents the tightened AD 
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thresholds and from Figure 10 which represents the original thresholds. From the tightened 
AD thresholds there is a 2% differential of AD conversion and a 9% differential of NAD 
conversion from the patient data set. The original thresholds resulted in a 10% differential 
of AD conversion and a 6% differential of NAD conversion from the patient data set. These 
differentials make sense because the percentage of patients that contracted AD increased 
when the AD thresholds were tightened compared against the original thresholds. The 
tightening of the AD threshold allows more patients to be classified as AD patients. 
Nonetheless both sets of thresholds were within a 10% difference compared against the 
original patient classification.  
Patient Data Set 
Tightened AD 
Thresholds 
(Figure 14) 
Original Thresholds 
(Figure 10) 
Outcome Probability Outcome Probability Outcome Probability 
AD 50% AD 48% AD 40% 
NAD 50% NAD 41% NAD 44% 
Table 19: Outcome Comparison 
The expected time periods could not be compared against the provided data set 
because that information was not provided. Therefore, the comparison of the expected time 
periods spent in transient states before visiting absorption states were conducted for the 
tightened AD thresholds, seen in Figure 15 against the original thresholds seen in Figure 
11. A F-test resulted in a F statistic of 1.30 and a F critical value of 1.67. Since the F statistic 
was smaller than the F critical value, this illustrates that variances between the two data 
sets are not significantly different and the expected number of time periods in the transient 
states between the two different thresholds are similar. The expected number of time 
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periods in transient states in Figures 11 and 15 never exceeded the time period of 1.  The 
maximum time spent in a transient state was 0.19 of a time period.  
4.2.2 Fixed Test Sequences  
Further Markov Chain model analysis was conducted to illustrate the impact fixed test 
sequences had on absorption probabilities and the expected time periods spent in transient 
states. The three tests: p-Tau, FDG-PET, and Hippo have six possible sequences:  
1) p-Tau → FDG-PET → Hippo 
2) FDG-PET → p-Tau → Hippo 
3) p-Tau → Hippo → FDG-PET 
4) Hippo → p-Tau → FDG-PET 
5) FDG-PET → Hippo → p-Tau 
6) Hippo → FDG-PET → p-Tau 
The following absorption probabilities are illustrated in Figure 16 for each fixed 
sequence above as well as the expected time spent in the transient states are illustrated in 
Figure 17. The transition matrixes for these six sequences equated to fewer amount of total 
states. The number of transient states for each test sequence was 3, while the number of 
absorbent states was 7. 
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Figure 16: Absorption Probabilities for All Fixed Test Sequences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Expected Time Periods in Transient States for All Fixed Test Sequences 
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4.2.2.a Experiment 2 Data Comparison 
 
One-Way ANOVA tests were conducted to compare all six sequences’ values of 
the absorption probabilities for states: [1, 1, 1, AD], [1, 1, 1, NAD], and [1, 1, 1, I]. These 
three states were compared to each other, because out of all the six tests these three states 
were the only absorption states that were similarly visited. The p-values for [1, 1, 1, AD], 
[1, 1, 1, NAD], and [1, 1, 1, I] were respectively 0.99, 0.89, and 0.97. The null hypothesis 
that states that all test means are equal, is not rejected and reveals that each different test 
sequence does not result in different absorption probabilities. This provides evidence that 
a fixed sequence does not impact the probability of patients contracting AD and not 
contracting AD. Table 20 shows the probabilities of contracting AD and not contracting 
AD (NAD) for each test sequence.  
1st Sequence 4th Sequence 
Outcome Probability Outcome Probability 
AD 34% AD 32% 
NAD 31% NAD 33% 
2nd Sequence 5th Sequence 
Outcome Probability Outcome Probability 
AD 31% AD 32% 
NAD 35% NAD 35% 
3rd Sequence 6th Sequence 
Outcome Probability Outcome Probability 
AD 32% AD 28% 
NAD 35% NAD 38% 
Table 20: Totaled Fixed Test Sequence Classification Probabilities 
These probabilities are compared to the 50% of patients contracting AD and the 
50% of patients not contracting AD (NAD) from the ADNI data. It can be seen from Table 
20 that the maximum difference from AD conversion among the test sequences and the 
patient data is 22% and the minimum difference of AD conversion against the patient data 
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is 10%. The best sequence for classifying AD patients is the 1st sequence and the worst 
sequence for classifying AD patients is the 6th sequence. The maximum difference between 
patient classification from the test sequences and the patient data for NAD contraction is 
19% and the minimum difference is 6%. The best sequence for classifying NAD patients 
is the 6th sequence and the worst sequence for NAD classification is the 1st sequence. 
Similarly, to the comparison done in 4.2.1.a, the Inconclusive patient classification could 
not be conducted because the patient data did not contain that information.  
 From the comparison analysis seen above, the patient contraction of AD and non-
contraction of AD (NAD) in the fixed test sequences are not as close to the original patient 
data classification as the original set thresholds from Figure 10 and the adjusted AD 
thresholds from Figure 14. The most accurate model of patient classification was conducted 
by the adjusted AD threshold model. 
A different comparison was conducted pertaining to the expected time spent in 
transient states. The expected time spent in different test sequences could not be compared 
across all test sequences at once because each test sequence resulted in different transient 
states. Testing sequences were then paired based upon similar transient states. Figure 18 
represents the plausible pairings. 
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Sequence 
#  [0,0,0, I] [1,1,0, I] 
Sequence 
#  [0,0,0, I] [1,1,0, I] 
1 
[0,0,0, I] 1 0.09589 
2 
[0,0,0, I] 1 0.097222 
[1,1,0, I] 0 1 [1,1,0, I] 0 1 
        
Sequence 
#  [0,0,0, I] [1,0,1, I] 
Sequence 
#  [0,0,0, I] [1,0,1, I] 
3 
[0,0,0, I] 1 0.097222 
4 
[0,0,0, I] 1 0.097222 
[1,0,1, I] 0 1 [1,0,1, I] 0 1 
        
Sequence 
#  [0,0,0, I] [1,1,0, I] 
Sequence 
#  [0,0,0, I] [1,1,0, I] 
5 
[0,0,0, I] 1 0.145833 
2 
[0,0,0, I] 1 0.097222 
[1,1,0, I] 0 1 [1,1,0, I] 0 1 
        
Sequence 
#  [0,0,0, I] [0,0,1, I] 
Sequence 
#  [0,0,0, I] [0,0,1, I] 
6 
[0,0,0, I] 1 0.409722 
4 
[0,0,0, I] 1 0.409722 
[0,0,1, I] 0 1 [0,0,1, I] 0 1 
Figure 18: Paired Expected Time Period Sequences 
Sequences 1 and 2, and sequences 5 and 2 are the only sequences that have differing 
expected time periods. The significance of these differences was calculated by conducting 
two separate F-tests on both pair of sequences. Sequences 1 and 2 are not statistically 
significant because its F statistic, 1.003 is smaller than the F critical value, 161.45. This is 
interpreted that both expected time periods for [1, 1, 0, I] are the same. Sequences 5 and 6 
are statistically different because its F value, 0.895, is larger than the F critical value, 
0.0062. This demonstrates that the expected time periods for [1, 1, 0, I] from sequences 5 
and 2 are different, as the expected time period is larger for sequence 5 than sequence 2. 
The comparison of expected time spent in transient periods could not be compared to the 
original thresholds and the adjusted AD thresholds because the number of transient states 
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was different among all three data sets. Additionally, the comparison against the patient 
data was not conducted because that information was not available. 
CHAPTER 5: CONCLUSIONS AND FUTURE WORK 
The importance of optimizing policy decisions about biomarker test administration 
impacts how soon a prognosis can be made regarding if a patient has contracted AD or not. 
AD has proven to be a disease that progresses over time. Along with time progression of a 
disease, there exists uncertain contributing factors to the contraction of AD. The need for 
medical decision-making models, such as Markov Chain models, allows the ability to 
model these stochastic factors. As referenced in 2.3, regarding the progression of 
HIV/AIDs, case studies have been used to demonstrate how Markov Chain models can be 
used in the healthcare industry. Markov Chain models allow researchers the ability to 
model the progression of diseases, optimize the procedure for prognosis, and decrease the 
associated healthcare costs. The STC had limitations that included the lack of ability to 
model dynamic factors associated with the progression of AD among different patient 
populations as well as the restriction of only modeling fixed test sequences. Based upon 
the biomarker tests’ values from STCs, the Markov Chain model provides a more robust 
way to predict the progression of AD.  
The methodology of the Markov Chain formulation was explained from the data 
collection to the calculation of the necessary probabilities needed to understand how many 
patients would contract the disease. Analysis was conducted based upon the probabilities 
to verify the accuracy of the Markov Chain model against a simulated model. The 
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experiment, using the Markov Chain model proved able to be simulated, based on different 
input parameters.  
  Based upon this verification, experiments were able to be conducted to 
demonstrate that alternating parameters of the Markov Chain model will yield different 
results in absorption probabilities and expected time periods spent in transient states. 
Absorption probabilities related information about how many patients would contract AD, 
not contract AD, and those that were inconclusive about contracting AD. The expected 
time periods spent in transient states demonstrated how long patients were expected to be 
unknowledgeable (Inconclusive) about their health state regarding AD. The first 
adjustment to the Markov Chain model was tightening the AD thresholds values and the 
second adjustment to the Markov Chain model was fixing certain test sequences. Revising 
the AD thresholds and implementing fixed test sequences to the Markov Chain model 
yielded different results and different interpretations. The adjustment of tightening the AD 
threshold, offered evidence that stricter AD thresholds resulted in fewer inconclusive 
states. On the other hand, fixed test sequences provided fewer transition states and 
demonstrated that fixed test sequences do not impact the absorption probabilities which 
affects the analysis of determining how many patients contract AD and those that do not. 
These experiments were additionally compared to the patient data set and revealed that the 
tightened AD threshold experiment proved to be the best model that closely matched the 
patient data classification. 
There exist different opportunities for future work regarding this research. It would 
be beneficial to validate the conversion of AD results of fixed test sequences from the 
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Markov Chain model against the STC model’s results. This verification was not conducted 
in this research because different data was provided to formulate the Markov Chain model 
versus the data tested by the STC model.  Additionally, further optimization of the 
thresholds could be conducted with different fixed sequences. The decision-making 
process of which tests to administer would be conducted by converting the formulated 
Markov Chain model to a Markov Decision Process.  
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